Literature DB >> 23092728

p21-activated kinases and gastrointestinal cancer.

Hong He1, Graham S Baldwin.   

Abstract

p21-activated kinases (PAKs) were initially identified as effector proteins downstream from GTPases of the Rho family. To date, six members of the PAK family have been discovered in mammalian cells. PAKs play important roles in growth factor signalling, cytoskeletal remodelling, gene transcription, cell proliferation and oncogenic transformation. A large body of research has demonstrated that PAKs are up-regulated in several human cancers, and that their overexpression is linked to tumour progression and resistance to therapy. Structural and biochemical studies have revealed the mechanisms involved in PAK signalling, and opened the way to the development of PAK-targeted therapies for cancer treatment. Here we summarise recent findings from biological and clinical research on the role of PAKs in gastrointestinal cancer, and discuss the current status of PAK-targeted anticancer therapies.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23092728     DOI: 10.1016/j.bbamcr.2012.10.015

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

Review 1.  Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.

Authors:  Yang-Guang Shao; Ke Ning; Feng Li
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

2.  Pak1 maintains epidermal stem cells by regulating Langerhans cells and is required for skin carcinogenesis.

Authors:  Kazuhiro Okumura; Megumi Saito; Yasuhiro Yoshizawa; Yuki Ito; Eriko Isogai; Kimi Araki; Yuichi Wakabayashi
Journal:  Oncogene       Date:  2020-05-19       Impact factor: 9.867

3.  β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation.

Authors:  Jun-Song Liu; Xiang-Ming Che; Shuai Chang; Guang-Lin Qiu; Shi-Cai He; Lin Fan; Wei Zhao; Zheng-Liang Zhang; Shu-Feng Wang
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

4.  PAK5-mediated E47 phosphorylation promotes epithelial-mesenchymal transition and metastasis of colon cancer.

Authors:  G Zhu; X Li; B Guo; Q Ke; M Dong; F Li
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

5.  Overexpression of PAK-1 is an independent predictor of disease recurrence in colorectal carcinoma.

Authors:  Jaudah Al-Maghrabi; Eman Emam; Wafaey Gomaa; Doaa Al-Qaydy; Basim Al-Maghrabi; Abdelbaset Buhmeida; Adel Abuzenadah; Mohammed Al-Qahtani; Mahmoud Al-Ahwal
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

6.  Over-expression of miR-193a-3p regulates the apoptosis of colorectal cancer cells by targeting PAK3.

Authors:  Tao Ma; Hai Li; Wenjing Yang; Quanxia Liu; Hui Yan
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

7.  p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines.

Authors:  Sung-Ung Moon; Jin Won Kim; Ji Hea Sung; Mi Hyun Kang; Se-Hyun Kim; Hyun Chang; Jeong-Ok Lee; Yu Jung Kim; Keun-Wook Lee; Jee Hyun Kim; Soo-Mee Bang; Jong Seok Lee
Journal:  Cancer Res Treat       Date:  2014-11-24       Impact factor: 4.679

8.  PAK4 regulates G6PD activity by p53 degradation involving colon cancer cell growth.

Authors:  Xiumei Zhang; Xia Zhang; Yang Li; Yangguang Shao; Jianying Xiao; Ge Zhu; Feng Li
Journal:  Cell Death Dis       Date:  2017-05-25       Impact factor: 8.469

9.  p21-activated kinase 7 is an oncogene in human osteosarcoma.

Authors:  Kun Han; Yan Zhou; Zhi-Hua Gan; Wei-Xiang Qi; Jian-Jun Zhang; Tao Fen; Wei Meng; Ling Jiang; Zan Shen; Da-Liu Min
Journal:  Cell Biol Int       Date:  2014-08-06       Impact factor: 3.612

10.  Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma.

Authors:  Zongtai Li; Xiaofang Zou; Liangxi Xie; Hongmei Dong; Yuping Chen; Qing Liu; Xiao Wu; David Zhou; Dongfeng Tan; Hao Zhang
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.